---
figid: PMC10150895__cm9-136-757-g002
figtitle: Emerging role of long non-coding RNA JPX in malignant processes and potential
  applications in cancers
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC10150895
filename: cm9-136-757-g002.jpg
figlink: /pmc/articles/PMC10150895/figure/F2/
number: F2
caption: 'Possible molecular mechanisms of JPX in human cancers. (A) JPX regulated
  miR-33a-5p/Twist1-mediated EMT progression by activating Wnt/β-catenin signaling
  in LC. (B) JPX functioned as a ceRNA for miR-145-5p to regulate cyclin D2 (CCND2)
  expression, and then promoted cell cycle progression in NSCLC. (C) JPX regulated
  NSCLC EMT by modulating miR-5195-3p/VEGFA axis. (D) JPX promoted CC progression
  by modulating miR-25-3p/SOX4 axis. (E) JPX was overexpressed in OSCC and promoted
  malignancy via miR-944/cadherin 2 (CDH2) axis. (F) JPX promoted GC progression by
  regulating C-X-C motif chemokine receptor 6 (CXCR6) and autophagy via inhibiting
  miR-197. (G) JPX contributed to the activation of extracellular signal-regulated
  kinase 1/2 (ERK1/2) and phosphatidylinositol3-kinase (PI3K)/AKT pathways via miRNAs/transforming
  growth factor β receptor (TGF-βR) axis, thus enhancing polyploidization and terminal
  maturation of megakaryocytes. (H) Anticancer effects of melatonin via regulating
  JPX/Wnt/β-catenin signaling pathway in human OS cells. (I) JPX promoted the progression
  of ovarian cancer through PI3K/Akt/mammalian target of rapamycin (mTOR) signaling
  pathway. CC: Cervical cancer; ceRNA: Competing endogenous RNA; EMT: Epithelial-mesenchymal
  transition; GC: Gastric cancer; LC: Lung cancer; LncRNA: Long noncoding RNA; miR:
  MircoRNA; NSCLC: Non-small cell lung cancer; OS: Osteosarcoma; OSCC: Oral squamous
  cell carcinoma; P: Phosphorylation; VEGFA: Vascular endothelial growth factor A.'
papertitle: Emerging role of long non-coding RNA JPX in malignant processes and potential
  applications in cancers.
reftext: Yuanyuan Wang, et al. Chin Med J (Engl). 2023 Apr 5;136(7):757-766.
year: '2023'
doi: 10.1097/CM9.0000000000002392
journal_title: Chinese Medical Journal
journal_nlm_ta: Chin Med J (Engl)
publisher_name: Lippincott Williams & Wilkins
keywords: Biomarker | Cancer | JPX | Long non-coding RNA | Therapeutic target
automl_pathway: 0.9109083
figid_alias: PMC10150895__F2
figtype: Figure
redirect_from: /figures/PMC10150895__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10150895__cm9-136-757-g002.html
  '@type': Dataset
  description: 'Possible molecular mechanisms of JPX in human cancers. (A) JPX regulated
    miR-33a-5p/Twist1-mediated EMT progression by activating Wnt/β-catenin signaling
    in LC. (B) JPX functioned as a ceRNA for miR-145-5p to regulate cyclin D2 (CCND2)
    expression, and then promoted cell cycle progression in NSCLC. (C) JPX regulated
    NSCLC EMT by modulating miR-5195-3p/VEGFA axis. (D) JPX promoted CC progression
    by modulating miR-25-3p/SOX4 axis. (E) JPX was overexpressed in OSCC and promoted
    malignancy via miR-944/cadherin 2 (CDH2) axis. (F) JPX promoted GC progression
    by regulating C-X-C motif chemokine receptor 6 (CXCR6) and autophagy via inhibiting
    miR-197. (G) JPX contributed to the activation of extracellular signal-regulated
    kinase 1/2 (ERK1/2) and phosphatidylinositol3-kinase (PI3K)/AKT pathways via miRNAs/transforming
    growth factor β receptor (TGF-βR) axis, thus enhancing polyploidization and terminal
    maturation of megakaryocytes. (H) Anticancer effects of melatonin via regulating
    JPX/Wnt/β-catenin signaling pathway in human OS cells. (I) JPX promoted the progression
    of ovarian cancer through PI3K/Akt/mammalian target of rapamycin (mTOR) signaling
    pathway. CC: Cervical cancer; ceRNA: Competing endogenous RNA; EMT: Epithelial-mesenchymal
    transition; GC: Gastric cancer; LC: Lung cancer; LncRNA: Long noncoding RNA; miR:
    MircoRNA; NSCLC: Non-small cell lung cancer; OS: Osteosarcoma; OSCC: Oral squamous
    cell carcinoma; P: Phosphorylation; VEGFA: Vascular endothelial growth factor
    A.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDH2
  - MIR944
  - EPHB2
  - MAPK1
  - MAPK3
  - MIR17
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - MIR197
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - JPX
  - CTNNB1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - CXCR6
  - GC
  - TWIST1
  - ITK
  - SLC22A3
  - CDH1
  - FZR1
  - VEGFA
  - CCND2
  - MTOR
  - SOX4
  - CXCR1
  - Erk7
  - rl
  - p38a
  - te
  - se
  - ref(2)P
  - DCTN4-p62
  - Tfb1
  - Nup62
  - Taf6
  - how
  - hi
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - arm
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - shg
  - CadN
  - Pvf1
  - CycE
  - cyc
  - Mtor
  - Tor
  - oc
  - Melatonin
  - SITTE
---
